Mild Cognitive Impairment – Pipeline Review, H1 2018 Market Report; Launched via MarketResearchReports.com
Mild cognitive impairment (MCI) is a condition involving problems with cognitive function (such as thinking, knowing and remembering). MCI is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. Symptoms include depression, irritability and aggression, anxiety and apathy. Risk factors include diabetes, high blood pressure, and depression, smoking and elevated cholesterol.
Report Highlights
Mild Cognitive Impairment - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Mild Cognitive Impairment (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 10, 6, 1 and 13 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.
Mild Cognitive Impairment (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences,
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Mild Cognitive Impairment (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Mild Cognitive Impairment (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Mild Cognitive Impairment (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Mild Cognitive Impairment (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Spanning over 120 pages "Mild Cognitive Impairment - Pipeline Review, H1 2018" report covers Introduction, Report Coverage, Mild Cognitive Impairment - Overview, Mild Cognitive Impairment -
Please visit this link for more details: https://www.marketresearchreports.com/global-markets-direct/mild-cognitive-impairment-pipeline-review-h1-2018
Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare
Related Reports;
Herpes Zoster (Shingles) - Pipeline Review, H1 2018 - Visit at - https://www.marketresearchreports.com/global-markets-direct/herpes-zoster-shingles-pipeline-review-h1-2018
Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H1 2018 - Visit at - https://www.marketresearchreports.com/global-markets-direct/epstein-barr-virus-hhv-4-infections-pipeline-review-h1-2018
About
Market Research Reports® Inc. is world's largest store offering quality market research, SWOT analysis, competitive intelligence and industry reports. We help Fortune 500 to Start-Ups with the latest market research reports on global & regional markets which comprise key industries, leading market players, new products and latest industry analysis & trends.
Contact us for your market research requirements: http://www.marketresearchreports.com/contact
For more information on this press release visit: http://www.sbwire.com/press-releases/mild-cognitive-impairment-pipeline-review-h1-2018-market-report-launched-via-marketresearchreportscom-953114.htm
Media Relations Contact
Telephone: 1-302-703-9904
Email: Click to Email
Web: https://www.marketresearchreports.com/global-markets-direct/mild-cognitive-impairment-pipeline-review-h1-2018
R– 3rd Party Insurance
Steven W. Lieberman Is Recognized, For A Record 16th Consecutive Year, As Summit Financial Resources Inc.’s Investment Leader
Advisor News
- How student loan debt impacts 401(k) balances
- The ‘sandwich generation’ faces compounded barriers to retirement savings
- Benefit Costs Squeeze Schools, Driving Cuts, Tax Hikes And Difficult Tradeoffs
- Why client insurance needs could change even if their life doesn’t
- Most Gen Z investors think less than a year ahead when making financial decisions
More Advisor NewsAnnuity News
- Oklahoma Insurance Dept. helps Oklahomans recover unclaimed life insurance benefits
- Bitcoin gains ground in retirement market with Equitable annuity option
- Best’s Special Report: First-Half 2026 Net Income in U.S. Life/Annuity Insurance Industry Dips Slightly
- The next phase of life insurance investing
- Ty J. Young Wealth Management Acquires Senior Insurance Services, Expanding Its Growing Annuity Firm: Ty J. Young Wealth Management
More Annuity NewsHealth/Employee Benefits News
Life Insurance News